Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Aboubakr Mohamed Elnashar

Benha University Hospital, Egypt

Title: Platelet-Rich Plasma In Reproductive Medicine: Current Status

Biography

Biography: Aboubakr Mohamed Elnashar

Abstract

Background: The successful use of PRP in regenerative medicine has led investigators to study its effect in the treatment of conditions like decreased ovarian reserve, poor responders, premature ovarian insufficiency, thin endometrium and Aschermann syndrome

Objective: To review the uses of PRP (intraovarian & intrauterine) in reproductive medicine.

Methods: A literature search for English articles related to the uses of PRP in reproductive medicine, including articles published in PubMed, from 2000 to August 2021.

Results: For intraovarian PRP: 17 studies were found: No RCT. Studies were classified according to indication. (1) For diminished ovarian reserve: 6 studies including 369 patients. (2). For poor responders: 3 case series studies including 41 patients with an improvement in ovarian response. (3) For premature ovarian insufficiency: 8 studies including 373 patients. Ovarian reserve markers were the outcome of all studies with conflicting results. LBR was not determined in the majority of studies. For Intrauterine PRP: 15 studies were found. Studies were classified according to indication. 1. For thin endometrium 10 studies including only 3 RCT with an improvement in endometrial thickness. 2. Aschermann syndrome: 4 studies (2 case series & 2 comparative studies) including 51 patients without significant benefit. 3. Chronic endometritis, one case report with successful treatment

Conclusion: Intraovarian PRP for diminished ovarian reserve, poor ovarian response, or POI is still experimental. Intrauterine PRP for thin endometrium is promising. Well-designed, large RCTS to confirm its efficacy and safety are required.